CETP inhibition is believed to potentially raise HDL (good cholesterol) levels and help prevent cardiovascular disease.
As per the deal, Simcere will receive exclusive rights to develop and commercialize BMS-795311 in China while Bristol-Myers Squibb will retain exclusive rights in all other markets.
The strengths of both the companies will help in the advancement of the delivery of clinical Phase IIa proof-of-concept.
The financial terms of the deal have not been disclosed.